Aker BioMarine recently reported how the company managed to grow sales and improve operations in the still-challenging omega-3 market, and continues to heavily invest in new technology and the development of new krill-derived products. Matts Johansen, CEO of Aker BioMarine, is satisfied with the result, but admitted that 2016 was still a challenging year for the company. Johansen said. “Although 2016 was a good year for Aker BioMarine, we posted slightly negative earnings after tax. The investments needed to build a supply chain for krill-based products, the resources needed to innovate and document their biological effects, and the time needed to develop new markets are reflected in our earnings.”
Upcoming webinars

The science of HMOs – A novonesis webinar featuring new clinical findings and ESPGHAN highlights
Novonesis
Register now

From boosters to companions: GLP-1 in Food, Beverages and Supplements
Rousselot
Register now

Texture challenges in high protein bars: Understanding the benefits of casein
Lactalis Ingredients
Register now
All upcoming webinars
Subscribe to our newsletters
By continuing to browse our site you agree to our Privacy Statement















